TAMPA, Fla.--(BUSINESS WIRE)--Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
TORONTO--(BUSINESS WIRE)--Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age. Dr Sheetal Sapra, MD, Board-certified Dermatologist and founder of ICLS D
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 22, 2022 and the issuance of stock options and restricted share units (“RSUs”). The results of the director elections were as follows: Name Votes in Favour % Votes in Favour Vot
VANCOUVER, British Columbia--(BUSINESS WIRE)--STEMCELL Technologies has received ISO 14001 Certification of its Environmental Management System.
VANCOUVER, British Columbia--(BUSINESS WIRE)--ABOzymes Biomedical Inc., today announced it has completed a substantially upsized seed financing. The funds will be used to further develop its ground-breaking proprietary platform that enables a world where a patient’s blood type is no longer the first constraint when they need life-saving organ transplants or blood transfusions. Built upon the discoveries of Dr. Peter Rahfeld, Professor Stephen G. Withers and Professor Jayachandran Kizzhakedathu
TORONTO & DALLAS--(BUSINESS WIRE)---- $PINK.V #AI--Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF)(FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, is pleased to announce that Mr. Anantha Kancherla has been appointed to its Board of Directors following his nomination by Social Capital, effective immediately. Jeremy Sobotta, Perimeter’s Chief Execu
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM). In June 2021, the FDA also granted Fast Track Designation for VBI-1901 for the treatment of recurrent GB
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported audited financial results for its fiscal year ended March 31, 2022 and recent business highlights. The Company also reiterated its anticipated pipeline and strategic milestones for the remainder of 2022. “Cybin made important progress across the board in recent months, accelerating both our pipeline o
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the drawdown of the remaining US$10 million available under its existing US$25 million debt facility led by Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"). This drawdown has been made available as the Company achieved a
VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for people with debilitating neurodegenerative disorders, today announced positive results from its pivotal bioequivalence study with ALPHA-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s Disease (AD). The study was de
TORONTO--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics is pleased to announce the launch of saypha® VOLUME PLUS, a hyaluronic acid dermal filler product specifically designed to restore facial volume. The updated release reads: CROMA AESTHETICS CANADA LAUNCHES SAYPHA® VOLUME PLUS Company will focus on untapped demographic groups that value aesthetics and a new definition of luxury Croma Aesthetics Canada
MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $MDX #SkinCancer--MedX Health receives final acceptance from the TSX Venture Exchange with respect to the issuance of Series II Convertible Loan Notes.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, announced the company is presenting preclinical data demonstrating that a next generation pneumococcal vaccine candidate incorporating a novel pneumococcal fusion protein conferred enhanced protection in a highly virulent model of serotype 3 invasive pneumococcal disease,
TORONTO--(BUSINESS WIRE)--(TSX: LWRK) LifeWorks Inc. (the “Company” or “LifeWorks”) announced today a cash dividend of $0.065 per share for the month of June 2022, to be paid on July 15, 2022 to holders of record of shares of LWRK on June 30, 2022. LifeWorks designates this dividend to be an “eligible dividend” pursuant to subsection 89(14) of the Income Tax Act (Canada) and similar provincial and territorial legislation. About LifeWorks LifeWorks is a world leader in providing digital and in-p
MANCHESTER, England--(BUSINESS WIRE)--Yourgene Health plc (“Yourgene”, AIM: YGEN), a leading international molecular diagnostics group, announces today the launch of the LightBench® Detect, the latest addition to its Ranger® Technology instrumentation portfolio at the 26th International Conference on Prenatal Diagnosis and Therapy (ISPD). The Company has worked closely with its clinical laboratory partners to develop size selection methodologies optimised for improving the performance of liquid
BURLINGTON, Ontario--(BUSINESS WIRE)--Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today the results of voting at its annual meeting of shareholders held on June 17, 2022 (the “Meeting”). Each of the matters voted upon at the Meeting as set out below is described in greater detail in the Notice of Annual Meeting of Shareholders and Management Information Circular of Anaergia dated May 5, 2022 (the “Circular”). There were present at the meeting registered shareholders and pr
DUBLIN--(BUSINESS WIRE)--The "Botulinum Toxin - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Botulinum Toxin Market to Reach $7.9 Billion by 2026 Global market for Botulinum Toxin estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2026, growing at a CAGR of 8.2% over the analysis period. Growth in the global market is driven by growing demand in medical/therapeutic and cosmetic a
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for momelotinib, an ACVR1 / ALK2, JAK1 and JAK2 inhibitor in development for the treatment of myelofibrosis. “Today is truly momentous for everyone at Sierra Oncology and the patients we serve. This team
